This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 586 |
respiratory tract | 511 |
hong kong | 315 |
respiratory viruses | 308 |
public health | 298 |
respiratory syndrome | 291 |
risk factors | 267 |
infectious diseases | 254 |
additional file | 248 |
pandemic influenza | 239 |
avian influenza | 233 |
respiratory infections | 232 |
influenza virus | 227 |
severe acute | 226 |
intensive care | 218 |
respiratory syncytial | 203 |
lower respiratory | 201 |
tract infections | 198 |
infect dis | 196 |
syncytial virus | 191 |
virus infection | 186 |
dis doi | 178 |
cord uid | 178 |
bmc infect | 178 |
doc id | 178 |
statistically significant | 167 |
years old | 154 |
united states | 153 |
clinical characteristics | 151 |
chain reaction | 150 |
polymerase chain | 150 |
acquired pneumonia | 149 |
novel coronavirus | 148 |
health care | 146 |
nucleic acid | 146 |
pregnant women | 143 |
infectious disease | 143 |
competing interests | 141 |
upper respiratory | 141 |
logistic regression | 138 |
informed consent | 134 |
mycoplasma pneumoniae | 132 |
care unit | 130 |
respiratory pathogens | 129 |
world health | 129 |
authors declare | 127 |
respiratory illness | 126 |
influenza viruses | 122 |
viral infections | 121 |
young children | 121 |
significantly higher | 120 |
syndrome coronavirus | 119 |
infection control | 118 |
critically ill | 118 |
respiratory disease | 118 |
respiratory virus | 118 |
confirmed cases | 117 |
least one | 116 |
study period | 116 |
health organization | 116 |
present study | 113 |
previous studies | 113 |
data collection | 110 |
middle east | 110 |
staphylococcus aureus | 109 |
respiratory distress | 109 |
systematic review | 108 |
human bocavirus | 105 |
final manuscript | 104 |
time pcr | 104 |
disease control | 103 |
ill patients | 102 |
east respiratory | 101 |
coronavirus disease | 101 |
clinical features | 100 |
saudi arabia | 100 |
nosocomial infections | 100 |
healthcare workers | 99 |
age group | 98 |
age groups | 98 |
distress syndrome | 97 |
tract infection | 96 |
cohort study | 96 |
seasonal influenza | 96 |
mechanical ventilation | 96 |
respiratory infection | 94 |
factors associated | 93 |
influenza pandemic | 93 |
streptococcus pneumoniae | 93 |
current study | 92 |
authors read | 92 |
index case | 90 |
multiplex pcr | 90 |
immune response | 89 |
severe disease | 86 |
virus infections | 86 |
sars patients | 85 |
influenza vaccination | 85 |
respiratory viral | 85 |
respiratory failure | 85 |
significant difference | 84 |
surveillance system | 84 |
written informed | 83 |
two groups | 83 |
performed using | 82 |
among patients | 81 |
like illness | 81 |
clinical symptoms | 80 |
statistical analysis | 78 |
disease severity | 78 |
institutional affiliations | 76 |
jurisdictional claims | 76 |
published maps | 76 |
remains neutral | 76 |
springer nature | 76 |
nature remains | 76 |
data analysis | 76 |
study design | 75 |
hospitalized patients | 75 |
confidence interval | 74 |
bacterial co | 74 |
antimicrobial resistance | 74 |
respiratory symptoms | 74 |
human metapneumovirus | 74 |
copies ml | 73 |
increased risk | 73 |
sample size | 73 |
median age | 72 |
among children | 72 |
case report | 72 |
general population | 70 |
ethics committee | 70 |
significant differences | 69 |
positive samples | 69 |
risk factor | 68 |
dengue fever | 67 |
case definition | 67 |
mortality rate | 66 |
significantly associated | 65 |
clinical manifestations | 63 |
inosine pranobex | 63 |
pcr assays | 63 |
reverse transcription | 62 |
tested positive | 61 |
control measures | 61 |
viral infection | 61 |
symptom onset | 61 |
supplementary material | 60 |
influenza vaccine | 60 |
hand hygiene | 60 |
entry screening | 60 |
associated pneumonia | 60 |
odds ratio | 60 |
viral load | 60 |
patients admitted | 59 |
parainfluenza virus | 59 |
clinical data | 59 |
viral respiratory | 59 |
hospital admission | 59 |
hospitalized children | 58 |
mortality rates | 58 |
regression analysis | 58 |
hospital stay | 57 |
virus detection | 57 |
pcr assay | 57 |
cmv infection | 57 |
positive patients | 57 |
severe pneumonia | 57 |
human adenovirus | 56 |
icu admission | 56 |
surveillance systems | 56 |
patients without | 56 |
control study | 55 |
detection rate | 55 |
drug sales | 55 |
chest ct | 55 |
confidence intervals | 55 |
severe respiratory | 55 |
sore throat | 54 |
test results | 54 |
corresponding author | 54 |
pneumoniae pneumonia | 54 |
severe cases | 53 |
ethics approval | 53 |
body temperature | 53 |
patients infected | 53 |
incubation period | 53 |
high risk | 53 |
respiratory samples | 53 |
incidence rate | 52 |
care units | 52 |
like symptoms | 52 |
dengue virus | 52 |
pneumonia patients | 52 |
resistant staphylococcus | 51 |
bacterial infections | 50 |
clinical presentation | 50 |
within days | 50 |
institutional review | 50 |
confirmed influenza | 49 |
case series | 49 |
significantly lower | 49 |
infected patients | 49 |
regression model | 49 |
significantly different | 49 |
influenza infection | 49 |
may also | 49 |
acute samples | 49 |
reactive protein | 49 |
clinical outcomes | 48 |
review board | 48 |
bacterial pathogens | 48 |
university hospital | 48 |
protective behaviors | 48 |
throat swabs | 47 |
study participants | 47 |
total number | 47 |
risk perception | 47 |
spatial autocorrelation | 47 |
note springer | 47 |
pediatric patients | 47 |
alere i | 46 |
lung disease | 46 |
mouth disease | 46 |
hemorrhagic fever | 46 |
adult patients | 46 |
patients received | 46 |
time reverse | 46 |
previously described | 46 |
viral rna | 45 |
household members | 45 |
montanide isa | 45 |
recombinant protein | 45 |
scan statistic | 45 |
knowledge transfer | 45 |
retrospective study | 44 |
infrared thermoscanners | 44 |
laboratory confirmed | 44 |
severe cap | 44 |
previous study | 44 |
pneumoniae colonization | 44 |
based surveillance | 44 |
two patients | 44 |
antibiotic resistance | 44 |
medical records | 43 |
preventive measures | 43 |
pue case | 43 |
placebo group | 43 |
relative humidity | 43 |
sample collection | 43 |
time series | 43 |
care workers | 43 |
spotted fever | 42 |
nosocomial infection | 42 |
i rsv | 42 |
young adults | 42 |
severe patients | 42 |
reasonable request | 42 |
positive results | 42 |
control group | 41 |
protective equipment | 41 |
regression models | 41 |
first case | 41 |
observational study | 41 |
respiratory diseases | 41 |
one patient | 41 |
influenza surveillance | 41 |
children aged | 41 |
statistical analyses | 41 |
developing countries | 41 |
pneumoniae infection | 41 |
higher risk | 41 |
inflammatory response | 41 |
statistical significance | 41 |
blood cell | 40 |
disease surveillance | 40 |
attack rate | 40 |
parainfluenza viruses | 40 |
hospital mortality | 40 |
elderly patients | 40 |
medical masks | 40 |
serum samples | 40 |
escherichia coli | 40 |
secondary cases | 40 |
surveillance data | 40 |
scrub typhus | 40 |
white blood | 40 |
urti pathogens | 39 |
severe leptospirosis | 39 |
five years | 39 |
emergency department | 39 |
national health | 39 |
infection rate | 39 |
publication history | 39 |
previous reports | 39 |
face mask | 38 |
missing data | 38 |
cov infection | 38 |
respiratory specimens | 38 |
viral detection | 38 |
hemophagocytic lymphohistiocytosis | 38 |
human coronavirus | 38 |
pulmonary disease | 38 |
adverse events | 38 |
patients hospitalized | 38 |
clinical samples | 38 |
square test | 38 |
citric acid | 37 |
septic shock | 37 |
common respiratory | 37 |
infected individuals | 37 |
confirmed case | 37 |
severe complications | 37 |
laboratory confirmation | 37 |
bacterial infection | 37 |
mean age | 37 |
pcr test | 37 |
sri lanka | 37 |
rsv infection | 37 |
sars coronavirus | 36 |
sichuan province | 36 |
clinical course | 36 |
antiviral therapy | 36 |
drug resistance | 36 |
femoral head | 36 |
acinetobacter baumannii | 36 |
southern china | 36 |
sectional study | 36 |
per year | 36 |
class i | 36 |
final version | 36 |
coronavirus infection | 36 |
previously reported | 36 |
exact test | 36 |
severe covid | 36 |
organ dysfunction | 36 |
personal protective | 36 |
influenza cases | 36 |
diagnostic tests | 35 |
acute lower | 35 |
contact tracing | 35 |
study protocol | 35 |
positive cases | 35 |
healthy adults | 35 |
among adults | 35 |
human cases | 35 |
npi implementation | 35 |
hand washing | 35 |
aged years | 35 |
influenza season | 35 |
pseudomonas aeruginosa | 35 |
human immunodeficiency | 34 |
pleural effusion | 34 |
cell count | 34 |
categorical variables | 34 |
community acquired | 34 |
high prevalence | 34 |
infectious agents | 34 |
children hospitalized | 34 |
transport medium | 34 |
family members | 33 |
novel influenza | 33 |
sars epidemic | 33 |
swab samples | 33 |
clinical diagnosis | 33 |
real time | 33 |
retrospective cohort | 33 |
biomed central | 33 |
odds ratios | 33 |
human infection | 33 |
respiratory pathogen | 33 |
nasal swab | 33 |
next manuscript | 33 |
disease burden | 33 |
infection rates | 33 |
poultry workers | 33 |
emerging infectious | 33 |
two weeks | 33 |
organ failure | 33 |
intervention arm | 33 |
adenovirus infection | 33 |
nasal swabs | 33 |
sales data | 33 |
respiratory picornaviruses | 32 |
datasets used | 32 |
first wave | 32 |
hiv infection | 32 |
index patients | 32 |
reported cases | 32 |
gold standard | 32 |
infections among | 32 |
less likely | 32 |
blood pressure | 32 |
new cases | 32 |
host proteins | 32 |
viral pathogens | 32 |
immunodeficiency virus | 32 |
different types | 32 |
search terms | 31 |
study population | 31 |
close contacts | 31 |
small number | 31 |
medical conditions | 31 |
hfrs incidence | 31 |
detection rates | 31 |
hubei province | 31 |
large number | 31 |
mrsa cases | 31 |
hemophagocytic syndrome | 31 |
multivariate analysis | 31 |
fatality rate | 31 |
supplementary information | 31 |
swab specimens | 31 |
adenovirus type | 31 |
also found | 31 |
antiviral treatment | 31 |
maternal morbidity | 31 |
hiv positivity | 31 |
hexavalent recombinant | 31 |
roma sinti | 30 |
poc testing | 30 |
molecular detection | 30 |
clinical trials | 30 |
health authorities | 30 |
microbial load | 30 |
see additional | 30 |
human respiratory | 30 |
prospective study | 30 |
stenotrophomonas maltophilia | 30 |
airborne transmission | 30 |
important role | 30 |
plasma samples | 30 |
cov cases | 30 |
hbov infection | 30 |
standard deviation | 30 |
rural areas | 30 |
typhoid fever | 30 |
study date | 30 |
endemic countries | 30 |
collected data | 30 |
household transmission | 30 |
wind speed | 29 |
amino acid | 29 |
underlying diseases | 29 |
age class | 29 |
potential risk | 29 |
analysis showed | 29 |
optimal control | 29 |
nosocomial transmission | 29 |
demographic characteristics | 29 |
reverse transcriptase | 29 |
temporal scan | 29 |
bone marrow | 29 |
mainland china | 29 |
antibiotic treatment | 29 |
urinary tract | 29 |
chronic obstructive | 29 |
diagnostic accuracy | 29 |
predictive value | 29 |
pao fio | 29 |
virus type | 29 |
bordetella pertussis | 29 |
clinical practice | 29 |
literature review | 29 |
study conducted | 28 |
early diagnosis | 28 |
children years | 28 |
household contacts | 28 |
publicly available | 28 |
wide range | 28 |
infant testing | 28 |
antimicrobial susceptibility | 28 |
nvhap bundle | 28 |
medical center | 28 |
negative group | 28 |
influenza transmission | 28 |
independently associated | 28 |
samples collected | 28 |
mg kg | 28 |
magna pure | 28 |
obstructive pulmonary | 28 |
immune responses | 28 |
skin coupon | 28 |
heart disease | 28 |
severe maternal | 28 |
patients aged | 28 |
several limitations | 28 |
second wave | 28 |
ntm lung | 28 |
negative results | 28 |
continuous variables | 28 |
blood culture | 28 |
igg antibodies | 28 |
malaria cases | 28 |
ii score | 28 |
multivariate logistic | 28 |
future studies | 28 |
direct contact | 28 |
incidence rates | 28 |
respiratory illnesses | 28 |
age distribution | 28 |
icu patients | 28 |
results suggest | 27 |
lung fibrosis | 27 |
haemophilus influenzae | 27 |
one study | 27 |
viral etiology | 27 |
timely infant | 27 |
controlled trial | 27 |
healthy controls | 27 |
interstitial lung | 27 |
confirmed covid | 27 |
online version | 27 |
nasopharyngeal swabs | 27 |
severe leukopenia | 27 |
inclusion criteria | 27 |
sd ns | 27 |
healthcare settings | 27 |
time rt | 27 |
high incidence | 27 |
heart failure | 27 |
five patients | 27 |
cfu ml | 27 |
total nucleic | 27 |
protective behaviours | 27 |
determine whether | 27 |
contains supplementary | 27 |
necrosis factor | 27 |
exposed infants | 27 |
described previously | 27 |
severe dengue | 27 |
laboratory findings | 27 |
inflammatory cytokines | 27 |
head necrosis | 27 |
log cfu | 26 |
coronavirus pneumonia | 26 |
written consent | 26 |
risk groups | 26 |
cases reported | 26 |
associated infections | 26 |
reproduction number | 26 |
cumulative number | 26 |
differential diagnosis | 26 |
two different | 26 |
febrile respiratory | 26 |
abdominal pain | 26 |
compared using | 26 |
icu stay | 26 |
per day | 26 |
clinical trial | 26 |
pulmonary tuberculosis | 26 |
clinically diagnosed | 26 |
rapid detection | 26 |
human infections | 26 |
computed tomography | 26 |
serum creatinine | 26 |
viral co | 26 |
antibiotic therapy | 26 |
myeloid cells | 26 |
active group | 26 |
protein mixture | 26 |
peripheral blood | 26 |
patients receiving | 26 |
high fever | 26 |
chronic respiratory | 26 |
viral transport | 26 |
health emergency | 25 |
th day | 25 |
indigenous children | 25 |
presumed consent | 25 |
adjusted odds | 25 |
epidemiological characteristics | 25 |
ts samples | 25 |
invasive ventilation | 25 |
will help | 25 |
laboratory tests | 25 |
educational programs | 25 |
drug withdrawal | 25 |
dengue infection | 25 |
human rabies | 25 |
viral pneumonia | 25 |
receptor expressed | 25 |
clinical outcome | 25 |
medical university | 25 |
kidney disease | 25 |
electronic supplementary | 25 |
toxocara toxascaris | 25 |
triggering receptor | 25 |
authorized users | 25 |
blood samples | 25 |
military recruits | 25 |
dengue patients | 25 |
renal syndrome | 25 |
influenza infections | 25 |
laboratory testing | 25 |
spa type | 25 |
time period | 25 |
primary care | 24 |
mini kit | 24 |
two cases | 24 |
nasopharyngeal swab | 24 |
dengue ns | 24 |
imported cases | 24 |
igm igg | 24 |
interquartile range | 24 |
syndromic surveillance | 24 |
negative patients | 24 |
psychological responses | 24 |
south korea | 24 |
tract disease | 24 |
year old | 24 |
cardiac involvement | 24 |
pathogen transfer | 24 |
medical profession | 24 |
hbov dna | 24 |
piperacillin tazobactam | 24 |
spa types | 24 |
kadoma city | 24 |
human coronaviruses | 24 |
high levels | 24 |
rate among | 24 |
severe illness | 24 |
avoidance behaviors | 24 |
time points | 24 |
human parainfluenza | 24 |
even though | 23 |
primary outcome | 23 |
internal medicine | 23 |
viral nucleic | 23 |
health commission | 23 |
infections due | 23 |
clinical specimens | 23 |
several studies | 23 |
illness among | 23 |
frequently detected | 23 |
study showed | 23 |
contact details | 23 |
nosocomial pathogens | 23 |
vaccination coverage | 23 |
pcr results | 23 |
conducted using | 23 |
clostridium difficile | 23 |
pneumonia caused | 23 |
toxoplasma gondii | 23 |
results showed | 23 |
cases among | 23 |
high mortality | 23 |
emergency response | 23 |
pcr testing | 23 |
nasopharyngeal aspirates | 23 |
respiratory panel | 23 |
high rate | 23 |
applied biosystems | 23 |
cell epitopes | 23 |
control arm | 23 |
previously healthy | 23 |
stainless steel | 23 |
children less | 23 |
phylogenetic analysis | 23 |
live poultry | 23 |
mask use | 23 |
swine flu | 23 |
virucidal activity | 23 |
sd bioline | 23 |
secondary bacterial | 23 |
positive result | 23 |
independent variables | 23 |
high rates | 23 |
immune system | 23 |
higher levels | 23 |
mean temperature | 22 |
teaching hospital | 22 |
measles outbreak | 22 |
time polymerase | 22 |
transcription polymerase | 22 |
orientia tsutsugamushi | 22 |
recent study | 22 |
without pneumonia | 22 |
epithelial cells | 22 |
infection among | 22 |
disease outbreak | 22 |
will also | 22 |
diabetes mellitus | 22 |
median time | 22 |
aerosol transmission | 22 |
epidemiological data | 22 |
membrane oxygenation | 22 |
infections caused | 22 |
molecular epidemiology | 22 |
general hospital | 22 |
multivariable logistic | 22 |
case fatality | 22 |
local health | 22 |
renal failure | 22 |
may lead | 22 |
factors may | 22 |
general public | 22 |
another study | 22 |
throat swab | 22 |
one month | 22 |
antiviral drugs | 22 |
large volume | 22 |
new york | 22 |
analyzed using | 22 |
elderly inpatients | 22 |
moraxella catarrhalis | 22 |
one virus | 22 |
tumor necrosis | 22 |
information accompanies | 22 |
study group | 22 |
lymphocyte count | 22 |
took place | 22 |
cause mortality | 22 |
pg ml | 22 |
risk awareness | 22 |
small sample | 21 |
underlying medical | 21 |
apache ii | 21 |
positively associated | 21 |
colonization frequency | 21 |
bronchoalveolar lavage | 21 |
participants will | 21 |
severe sepsis | 21 |
upper airway | 21 |
process indicators | 21 |
central taiwan | 21 |
multiplex real | 21 |
leukocyte count | 21 |
fever screening | 21 |
pandemic virus | 21 |
pneumococcal conjugate | 21 |
genome sequence | 21 |
prevention measures | 21 |
epidemic size | 21 |
viruses detected | 21 |
early detection | 21 |
surveillance program | 21 |
enveloped viruses | 21 |
studies reported | 21 |
lf caa | 21 |
allelic discrimination | 21 |
demographic data | 21 |
influenza seasons | 21 |
commercially available | 21 |
picu stay | 21 |
ntm treatment | 21 |
study also | 21 |
tract samples | 21 |
nucleic acids | 21 |
exclusion criteria | 21 |
first reported | 21 |
multiple organ | 21 |
ct findings | 21 |
european countries | 21 |
subjects less | 21 |
retrospective analysis | 21 |
requiring hospitalization | 21 |
local transmission | 21 |
positive rate | 21 |
adjusted incidence | 21 |
patient data | 20 |
clinical signs | 20 |
international airport | 20 |
samples tested | 20 |
factors influencing | 20 |
occupational risks | 20 |
chest radiograph | 20 |
adults hospitalized | 20 |
extracorporeal membrane | 20 |
analytical sensitivity | 20 |
filmarray rp | 20 |
one week | 20 |
sputum samples | 20 |
critical care | 20 |
acid testing | 20 |
one year | 20 |
blood cultures | 20 |
innate immune | 20 |
positivity rate | 20 |
transmission dynamics | 20 |
care homes | 20 |
study found | 20 |
response rate | 20 |
cluster areas | 20 |
critical review | 20 |
pathogen transmission | 20 |
considered statistically | 20 |
associated hemophagocytic | 20 |
arima model | 20 |
hospital settings | 20 |
human rhinovirus | 20 |
patient population | 20 |
host immune | 20 |
laboratory data | 20 |
false negative | 20 |
also showed | 20 |
cases per | 20 |
severe community | 20 |
invasive mechanical | 20 |
also reported | 20 |
significantly increased | 20 |
chronic kidney | 20 |
patients presenting | 20 |
sars outbreak | 20 |
emerging respiratory | 20 |
clinical information | 20 |
pure lc | 20 |
epidemiological studies | 20 |
linear regression | 20 |
outpatient ed | 20 |
transmission events | 20 |
global burden | 20 |
better understanding | 20 |
pilot study | 20 |
exponential growth | 20 |
mycophenolate mofetil | 20 |
weaned group | 20 |
early stages | 20 |
linked immunosorbent | 20 |
research ethics | 20 |
tested using | 20 |
closely related | 20 |
three groups | 20 |
data used | 20 |
murine typhus | 20 |
influenza vaccines | 20 |
transplant recipients | 20 |
working group | 20 |
normal range | 20 |
included studies | 19 |
also significantly | 19 |
terminal time | 19 |
sars period | 19 |
recent years | 19 |
dengue duo | 19 |
index cases | 19 |
differ significantly | 19 |
take full | 19 |
viridans streptococci | 19 |
origin influenza | 19 |
randomly selected | 19 |
sentinel surveillance | 19 |
full advantage | 19 |
negative control | 19 |
human rhinoviruses | 19 |
secondary vitro | 19 |
significant association | 19 |
isothermal amplification | 19 |
disease caused | 19 |
univariate analysis | 19 |
richards model | 19 |
dengue acute | 19 |
rapid diagnostic | 19 |
nitric oxide | 19 |
see table | 19 |
following criteria | 19 |
acquired infections | 19 |
sf cells | 19 |
chronic lung | 19 |
fatal cases | 19 |
primary case | 19 |
high level | 19 |
case number | 19 |
pathogens detected | 19 |
suspected cases | 19 |
subgroup analysis | 19 |
elderly people | 19 |
stem cell | 19 |
higher mortality | 19 |
days prior | 19 |
author details | 19 |
resistant bacteria | 19 |
renal function | 19 |
older adults | 19 |
immunosorbent assay | 19 |
human adenoviruses | 19 |
mg dl | 19 |
different age | 19 |
case patients | 19 |
patient care | 19 |
endemic areas | 19 |
clinical settings | 19 |
cell culture | 19 |
epidemic season | 19 |
antibiotic use | 19 |
meteorological conditions | 19 |
may help | 19 |
test viruses | 19 |
kidney injury | 19 |
meteorological factors | 19 |
accession number | 19 |
transmission tree | 19 |
common symptoms | 19 |
indirect transfer | 19 |
early stage | 19 |
nasopharyngeal aspirate | 19 |
lung injury | 19 |
pcr products | 19 |
tick bite | 19 |
communityacquired pneumonia | 18 |
case reports | 18 |
vaccination status | 18 |
increasing age | 18 |
operating characteristic | 18 |
strongly associated | 18 |
based study | 18 |
dengue hemorrhagic | 18 |
respiratory rate | 18 |
common cold | 18 |
multiple viruses | 18 |
underlying chronic | 18 |
negative samples | 18 |
study site | 18 |
risk areas | 18 |
broad spectrum | 18 |
may increase | 18 |
control groups | 18 |
laboratory diagnosis | 18 |
disease outbreaks | 18 |
chinese center | 18 |
much lower | 18 |
macrolide resistance | 18 |
rna extraction | 18 |
ct scan | 18 |
resistance genes | 18 |
also used | 18 |
primary mers | 18 |
sensitivity analysis | 18 |
human influenza | 18 |
medical history | 18 |
specimen collection | 18 |
authors contributed | 18 |
recombinase polymerase | 18 |
pcr methods | 18 |
hla class | 18 |
adverse reactions | 18 |
rrna gene | 18 |
commonly used | 18 |
bacterial pneumonia | 18 |
patients showed | 18 |
mrsa clusters | 18 |
early phase | 18 |
data collected | 18 |
pediatric department | 18 |
data analyses | 18 |
universal vaccination | 18 |
coronavirus infections | 18 |
unsuccessfully weaned | 18 |
febrile illness | 18 |
study demonstrated | 18 |
bartonella henselae | 18 |
sputum specimens | 18 |
assessed using | 18 |
case i | 18 |
older population | 18 |
descriptive study | 18 |
health workers | 18 |
among hcws | 18 |
prospective cohort | 18 |
ill household | 18 |
multiple infections | 18 |
barr virus | 18 |
whole genome | 18 |
disease onset | 18 |
ns igm | 18 |
pneumococcal pneumonia | 18 |
data sources | 18 |
virus transmission | 18 |
receiver operating | 18 |
kong chinese | 18 |
antibiotic susceptibility | 18 |
igm antibodies | 18 |
acute kidney | 18 |
relatively high | 18 |
disease transmission | 18 |
independent risk | 18 |
included patients | 18 |
bioline dengue | 18 |
results may | 18 |
control subjects | 18 |
diseases society | 18 |
axillary temperature | 18 |
pathogenic avian | 17 |
time point | 17 |
mixed viral | 17 |
tract diseases | 17 |
complete genome | 17 |
ed patients | 17 |
susceptibility testing | 17 |
bocavirus infection | 17 |
close contact | 17 |
severe clinical | 17 |
pcr tests | 17 |
tertiary care | 17 |
pulmonary edema | 17 |
clinical cure | 17 |
negative predictive | 17 |
negative perception | 17 |
universal influenza | 17 |
antibody test | 17 |
female ratio | 17 |
saharan africa | 17 |
dvv rki | 17 |
medical care | 17 |
molecular typing | 17 |
generation sequencing | 17 |
transcriptase polymerase | 17 |
calculated using | 17 |
seasonal epidemic | 17 |
coronavirus hku | 17 |
united kingdom | 17 |
mycobacterium tuberculosis | 17 |
common pathogens | 17 |
acute phase | 17 |
polymerase amplification | 17 |
older patients | 17 |
google scholar | 17 |
google trends | 17 |
first time | 17 |
laboratory results | 17 |
randomized controlled | 17 |
cell counts | 17 |
air pollution | 17 |
pulmonary infiltrate | 17 |
longer duration | 17 |
older age | 17 |
reference laboratory | 17 |
clinical management | 17 |
antimicrobial agents | 17 |
severe influenza | 17 |
commonly detected | 17 |
pranobex group | 17 |
microbial community | 17 |
clinical presentations | 17 |
pneumonia among | 17 |
leading cause | 17 |
every step | 17 |
using spss | 17 |
days later | 17 |
suspected fraction | 17 |
ethical approval | 17 |
clinical findings | 17 |
clinical study | 17 |
male sex | 17 |
enterococcus faecium | 17 |
infection prevention | 17 |
study sites | 17 |
hpiv types | 17 |
southeast china | 17 |
blood cells | 17 |
increased mortality | 17 |
spss inc | 17 |
fever patients | 17 |
death rate | 17 |
pathogens causing | 16 |
level public | 16 |
case data | 16 |
highly pathogenic | 16 |
exposure time | 16 |
acute dengue | 16 |
viral panel | 16 |
gene polymorphisms | 16 |
narita international | 16 |
preventive behaviors | 16 |
sheep pen | 16 |
reported incidence | 16 |
ecmo support | 16 |
vaccine coverage | 16 |
health department | 16 |
vaccine candidate | 16 |
like illnesses | 16 |
rickettsial infections | 16 |
lung transplantation | 16 |
cov rna | 16 |
pneumococcal disease | 16 |
th july | 16 |
patients presented | 16 |
environmental contamination | 16 |
mh group | 16 |
virus types | 16 |
study arms | 16 |
internet search | 16 |
care setting | 16 |
study drug | 16 |
hajj pilgrims | 16 |
case control | 16 |
inanimate surfaces | 16 |
pue system | 16 |
mild disease | 16 |
early warning | 16 |
successfully weaned | 16 |
xtag respiratory | 16 |
influenza among | 16 |
molecular characterization | 16 |
patients diagnosed | 16 |
observational studies | 16 |
epidemic characteristics | 16 |
tmp smx | 16 |
daily new | 16 |
healthy children | 16 |
lung diseases | 16 |
patients died | 16 |
roche diagnostics | 16 |
rapid test | 16 |
patchy shadows | 16 |
global health | 16 |
pneumonia mortality | 16 |
reference standard | 16 |
excess rates | 16 |
haemorrhagic fever | 16 |
one third | 16 |
incidence density | 16 |
table shows | 16 |
tuberculosis drugs | 16 |
year period | 16 |
using stata | 16 |
affiliated hospital | 16 |
epidemic curves | 16 |
influenza epidemics | 16 |
salmonella enterica | 16 |
higher rate | 16 |
older people | 16 |
gastrointestinal symptoms | 16 |
protective measures | 16 |
genome sequencing | 16 |
diagnostic criteria | 16 |
immunocompetent patients | 16 |
care facilities | 16 |
also associated | 16 |
elution volume | 16 |
rna viruses | 16 |
days lost | 16 |
reproductive number | 16 |
spectrum antibiotics | 16 |
remains unclear | 16 |
times higher | 16 |
fri cases | 16 |
protective effect | 16 |
median duration | 16 |
febrile neutropenic | 16 |
viral etiologies | 16 |
higher proportion | 16 |
tract illness | 16 |
suspect cases | 16 |
results indicated | 16 |
least two | 16 |
negative cases | 16 |
study may | 16 |
infected cases | 16 |
severe ards | 15 |
thorough peer | 15 |
peer review | 15 |
recombinant proteins | 15 |
behavioral responses | 15 |
invasive pneumococcal | 15 |
case presentation | 15 |
endothelial cell | 15 |
based hand | 15 |
male patients | 15 |
general practitioners | 15 |
disease prevention | 15 |
online submission | 15 |
aged less | 15 |
treatment strategies | 15 |
underlying conditions | 15 |
recovered patients | 15 |
ten surveys | 15 |
higher incidence | 15 |
blood gas | 15 |
two viruses | 15 |
hiv aids | 15 |
molecular techniques | 15 |
tenofovir alafenamide | 15 |
published studies | 15 |
mediated isothermal | 15 |
action plan | 15 |
lung transplant | 15 |
rickettsial infection | 15 |
tuberculosis treatment | 15 |
room temperature | 15 |
correlation coefficient | 15 |
critical illness | 15 |
environmental factors | 15 |
pandemic period | 15 |
atypical pneumonia | 15 |
breast feeding | 15 |
old male | 15 |
sars susceptibility | 15 |
conjugate vaccine | 15 |
turning points | 15 |
soluble triggering | 15 |
central hospital | 15 |
behavioral change | 15 |
attack rates | 15 |
perceived efficacy | 15 |
false positive | 15 |
population density | 15 |
medical record | 15 |
systematic reviews | 15 |
blood sample | 15 |
severe group | 15 |
virotrack dengue | 15 |
average number | 15 |
direct transfer | 15 |
space constraints | 15 |
three patients | 15 |
common viral | 15 |
college station | 15 |
bacterial respiratory | 15 |
tertiary hospital | 15 |
convenient online | 15 |
immunocompromised patients | 15 |
index patient | 15 |
health interventions | 15 |
mild dengue | 15 |
internal control | 15 |
quality control | 15 |
north america | 15 |
vital signs | 15 |
clinical case | 15 |
three studies | 15 |
antiviral agents | 15 |
pulmonary infiltrates | 15 |
nervous system | 15 |
two years | 15 |
resistant mycoplasma | 15 |
children admitted | 15 |
viral hepatitis | 15 |
picu admissions | 15 |
patient days | 15 |
higher rates | 15 |
three times | 15 |
infections may | 15 |
zhejiang province | 15 |
necrotizing pneumonia | 15 |
resistance mutations | 15 |
demographic information | 15 |
among young | 15 |
acute cholecystitis | 15 |
randomised controlled | 15 |
one hundred | 15 |
severely ill | 15 |
outbreak detection | 15 |
compartmental model | 15 |
bloodstream infections | 15 |
external lysis | 15 |
negative psychological | 15 |
immediate publication | 15 |
estimated median | 15 |
chlamydia pneumoniae | 15 |
lower mortality | 15 |
malaria prevalence | 15 |
epidemic year | 15 |
illness onset | 15 |
freely available | 15 |
previously published | 15 |
treatment groups | 15 |
total population | 15 |
seven days | 15 |
five days | 15 |
patients may | 15 |
data will | 14 |
significantly greater | 14 |
serum sars | 14 |
climate conditions | 14 |
active surveillance | 14 |
cross correlations | 14 |
six patients | 14 |
ncov pneumonia | 14 |
among healthcare | 14 |
south african | 14 |
poisson regression | 14 |
temporal distribution | 14 |
animals within | 14 |
laboratory characteristics | 14 |
nk cells | 14 |
healthcare setting | 14 |
face masks | 14 |
first days | 14 |
within hours | 14 |
associated infection | 14 |
likely cluster | 14 |
common cause | 14 |
sd dengue | 14 |
may result | 14 |
antigen detection | 14 |
first year | 14 |
healthcare worker | 14 |
related hps | 14 |
acute specimens | 14 |
diagnostic test | 14 |
acute physiology | 14 |
class suspension | 14 |
health services | 14 |
causative agent | 14 |
accept influenza | 14 |
induced ards | 14 |
first study | 14 |
binding lectin | 14 |
study will | 14 |
consent argument | 14 |
extracted using | 14 |
pneumonia cases | 14 |
hospital setting | 14 |
cytokine production | 14 |
statistical computing | 14 |
pathogens including | 14 |
study included | 14 |
bacterial growth | 14 |
children without | 14 |
cov educational | 14 |
higher bmi | 14 |
serial interval | 14 |
pharyngeal swabs | 14 |
infected pneumonia | 14 |
valentine leukocidin | 14 |
viral particles | 14 |
human research | 14 |
molecular diagnostics | 14 |
gamma distribution | 14 |
recent studies | 14 |
patients tested | 14 |
roc curve | 14 |
measles outbreaks | 14 |
pcr amplification | 14 |
lymphocytes secreting | 14 |
meteorological data | 14 |
leukocytes ml | 14 |
child transmission | 14 |
intravenous immunoglobulin | 14 |
influenza propagation | 14 |
respir viruses | 14 |
plasma leakage | 14 |
secondary infection | 14 |
transmission rates | 14 |
plasmodium falciparum | 14 |
transfer rates | 14 |
resistant strains | 14 |
pue cases | 14 |
vaccine effectiveness | 14 |
moving average | 14 |
febrile neutropenia | 14 |
measles virus | 14 |
military personnel | 14 |
individual hcovs | 14 |
first two | 14 |
health education | 14 |
publication bias | 14 |
glycosylation sites | 14 |
cytomegalovirus infection | 14 |
multiple viral | 14 |
oxygen saturation | 14 |
confounding factors | 14 |
otherwise healthy | 14 |
among infants | 14 |
infections occurred | 14 |
tested negative | 14 |
health threat | 14 |
respiratory complaints | 14 |
virus rna | 14 |
detection methods | 14 |
data obtained | 14 |
hadv infection | 14 |
risk assessment | 14 |
health surveillance | 14 |
clinically relevant | 14 |
liver function | 14 |
described elsewhere | 14 |
north china | 14 |
many patients | 14 |
fall winter | 14 |
rvp assay | 14 |
including influenza | 14 |
positive predictive | 14 |
maternal mortality | 14 |
reporting system | 14 |
tb incidents | 14 |
hbov infections | 14 |
spatial clustering | 14 |
volume kit | 14 |
resistant pathogens | 14 |
medical staff | 14 |
laboratory test | 14 |
hospitalized cases | 14 |
ev isolates | 14 |
data regarding | 14 |
final status | 13 |
gro kc | 13 |
acid extraction | 13 |
acute lung | 13 |
mass media | 13 |
surveillance study | 13 |
air travel | 13 |
intervention groups | 13 |
health problem | 13 |
preventive behaviours | 13 |
wind velocity | 13 |
viral agents | 13 |
hiv positive | 13 |
streptococcus pyogenes | 13 |
confirmed diagnosis | 13 |
null hypothesis | 13 |
higher among | 13 |
coronary artery | 13 |
one sample | 13 |
lc instrument | 13 |
personal history | 13 |
scanning window | 13 |
considered significant | 13 |
time scan | 13 |
high sensitivity | 13 |
body mass | 13 |
early recognition | 13 |
herd immunity | 13 |
without related | 13 |
rsv test | 13 |
widely used | 13 |
vaccination rate | 13 |
hospital discharge | 13 |
significance level | 13 |
control policy | 13 |
collected clinical | 13 |
analysis set | 13 |
shandong province | 13 |
virus strain | 13 |
may contribute | 13 |
live bird | 13 |
estimated using | 13 |
perceived susceptibility | 13 |
virus detected | 13 |
study reported | 13 |
literature search | 13 |
three years | 13 |
polyomavirus sv | 13 |
baseline characteristics | 13 |
received antibiotics | 13 |
childhood pneumonia | 13 |
positive specimens | 13 |
measles patients | 13 |
urine output | 13 |
generation interval | 13 |
findings suggest | 13 |
simultaneous detection | 13 |
struvite group | 13 |
concern score | 13 |
disease progression | 13 |
may cause | 13 |
salmonella typhi | 13 |
vertical transmission | 13 |
selection bias | 13 |
influenzae type | 13 |
multiplex assays | 13 |
month period | 13 |
dengue cases | 13 |
cluster id | 13 |
three multiplex | 13 |
chlamydophila pneumoniae | 13 |
may reflect | 13 |
adherence status | 13 |
caa test | 13 |
way anova | 13 |
near miss | 13 |
fever group | 13 |
cure rates | 13 |
municipal water | 13 |
infection may | 13 |
per month | 13 |
descriptive statistics | 13 |
shock syndrome | 13 |
french guiana | 13 |
serum levels | 13 |
adenovirus infections | 13 |
respiratory support | 13 |
pharmaceutical interventions | 13 |
ng ml | 13 |
using real | 13 |
group compared | 13 |
single hadv | 13 |
mass index | 13 |
age classes | 13 |
isolation room | 13 |
severe infection | 13 |
highly infectious | 13 |
organizing pneumonia | 13 |
gene sequences | 13 |
prepub key | 13 |
relative risk | 13 |
pue surveillance | 13 |
influenza epidemic | 13 |
standard deviations | 13 |
asymptomatic children | 13 |
qiaamp viral | 13 |
toxocara spp | 13 |
measles vaccination | 13 |
immunofluorescence assay | 13 |
provided written | 13 |
clinical relevance | 13 |
local cases | 13 |
case reporting | 13 |
pandemic seasons | 13 |
clinical setting | 13 |
pathogen detection | 13 |
study shows | 13 |
bronchiolitis obliterans | 13 |
one patients | 13 |
discrimination assays | 13 |
autocorrelation analysis | 13 |
better understand | 13 |
measles cases | 13 |
systemic influenza | 13 |
epidemic curve | 13 |
hematologic malignancies | 13 |
three cases | 13 |
year study | 13 |
healthcare facilities | 13 |
cell transplantation | 13 |
promoter region | 13 |
south africa | 13 |
determined using | 13 |
many countries | 13 |
family cluster | 12 |
median value | 12 |
gastrointestinal illness | 12 |
may vary | 12 |
unconfirmed beliefs | 12 |
mrsa outbreaks | 12 |
healthy individuals | 12 |
molecular epidemiological | 12 |
us cdc | 12 |
average daily | 12 |
linked glycosylation | 12 |
different viruses | 12 |
notifiable diseases | 12 |
comorbidity status | 12 |
human enterovirus | 12 |
emergency departments | 12 |
high viral | 12 |
first draft | 12 |
transmission parameter | 12 |
canadian incidence | 12 |
information system | 12 |
infants born | 12 |
asymptomatic infection | 12 |
alanine aminotransferase | 12 |
intervention period | 12 |
high morbidity | 12 |
ili cases | 12 |
data may | 12 |
hemoglobin level | 12 |
oligonucleotide probes | 12 |
ns antigen | 12 |
pharyngeal swab | 12 |
asymptomatic uti | 12 |
conditional logistic | 12 |
infectious origin | 12 |
clinical studies | 12 |
blood donors | 12 |
within one | 12 |
three different | 12 |
log ml | 12 |
diagnostic tool | 12 |
common among | 12 |
asymptomatic patients | 12 |
intellectual content | 12 |
underlying disease | 12 |
vaccination rates | 12 |
pulmonary haemorrhage | 12 |
national influenza | 12 |
analysis indicated | 12 |
avian flu | 12 |
study clinical | 12 |
chinese patients | 12 |
virus positivity | 12 |
diagnostic methods | 12 |
genome sequences | 12 |
neonatal death | 12 |
intestinal infectious | 12 |
considered positive | 12 |
information regarding | 12 |
pneumonia requiring | 12 |
early identification | 12 |
randomly assigned | 12 |
two studies | 12 |
china date | 12 |
high proportion | 12 |
quality assessment | 12 |
acute renal | 12 |
child health | 12 |
mhc class | 12 |
cause severe | 12 |
market workers | 12 |
lung tissue | 12 |
epidemic data | 12 |
potential pathogens | 12 |
affective measures | 12 |
susceptibility profiles | 12 |
spatial analysis | 12 |
negative bacteria | 12 |
statistical software | 12 |
mice vaccinated | 12 |
emerg infect | 12 |
phase ii | 12 |
results indicate | 12 |
susceptible individuals | 12 |
chronic conditions | 12 |
urban areas | 12 |
molecular methods | 12 |
newly identified | 12 |
detection dogs | 12 |
gel electrophoresis | 12 |
health organisation | 12 |
ongoing disease | 12 |
rabies cases | 12 |
rna mini | 12 |
proposed method | 12 |
related ongoing | 12 |
pneumoniae infections | 12 |
acute infection | 12 |
igm rdt | 12 |
growth rate | 12 |
physical examination | 12 |
software version | 12 |
response options | 12 |
among exposed | 12 |
turning point | 12 |
central nervous | 12 |
analysed using | 12 |
pneumonia due | 12 |
reported case | 12 |
gene expression | 12 |
allele frequencies | 12 |
respiratory protection | 12 |
local implementation | 12 |
cytokine profile | 12 |
electronic medical | 12 |
county level | 12 |
occurred within | 12 |
studies showed | 12 |
healthcare personnel | 12 |
mononuclear cells | 12 |
cystic fibrosis | 12 |
rapid diagnosis | 12 |
otitis media | 12 |
vaccine development | 12 |
implementation teams | 12 |
much higher | 12 |
highly sensitive | 12 |
national reference | 12 |
clinical significance | 12 |
influenza outbreak | 12 |
investigation team | 12 |
many studies | 12 |
least years | 12 |
terminal cleaning | 12 |
study results | 12 |
environmental surfaces | 12 |
influenza activity | 12 |
enrolled patients | 12 |
large scale | 12 |
less frequently | 12 |
receive vaccination | 12 |
inflammatory syndrome | 12 |
emotional distress | 12 |
respiratory sample | 12 |
beta interferon | 12 |
flu outbreak | 12 |
advisory committee | 12 |
hospitalization among | 12 |
seasonal trends | 12 |
diagnostic performances | 12 |
average cellularity | 12 |
epidemiological study | 12 |
random effects | 12 |
resistant organisms | 12 |
rki guideline | 12 |
recall bias | 12 |
analysis revealed | 12 |
training period | 12 |
compartmental models | 12 |
medical intensive | 12 |
risk group | 12 |
low inoculum | 12 |
neuraminidase inhibitors | 12 |
data generated | 12 |
frequently found | 12 |
study aims | 12 |
income countries | 12 |
beijing chinese | 12 |
likely due | 12 |
may occur | 12 |
schistosoma infections | 12 |
chest radiography | 12 |
influenza sentinel | 12 |
male gender | 12 |
vaccinia virus | 12 |
lymph node | 12 |
primary infection | 12 |
secondary outcomes | 12 |
complement system | 12 |
thoracic society | 12 |
mild cases | 12 |
four patients | 12 |
one case | 12 |
ace i | 11 |
versus intermittent | 11 |
health facilities | 11 |
patient groups | 11 |
resistance mechanisms | 11 |
glass opacities | 11 |
flight passengers | 11 |
disease group | 11 |
surgical site | 11 |
squared test | 11 |
ha incidence | 11 |
neutropenic patients | 11 |
one respiratory | 11 |
year age | 11 |
aged children | 11 |
influenza pneumonia | 11 |
every year | 11 |
seasonal patterns | 11 |
global public | 11 |
university medical | 11 |
care system | 11 |
virus circulation | 11 |
phylogenetic tree | 11 |
low levels | 11 |
infectious individuals | 11 |
environmental conditions | 11 |
parents guardians | 11 |
cognitive risk | 11 |
lazio region | 11 |
cumulative deaths | 11 |
experimental peptide | 11 |
absolute humidity | 11 |
single virus | 11 |
adult respiratory | 11 |
ct value | 11 |
troponin i | 11 |
may play | 11 |
clinical efficacy | 11 |
secreting ifn | 11 |
coronavirus nl | 11 |
data suggest | 11 |
watery diarrhoea | 11 |
basic reproduction | 11 |
behaviour change | 11 |
common virus | 11 |
enhanced surveillance | 11 |
seasonal pattern | 11 |
significantly better | 11 |
molecular testing | 11 |
outcome variables | 11 |
diagnostic testing | 11 |
community transmission | 11 |
different countries | 11 |
frequently identified | 11 |
filmarray respiratory | 11 |
secondary dengue | 11 |
epidemic seasons | 11 |
daily number | 11 |
chongqing medical | 11 |
group included | 11 |
picu patients | 11 |
less common | 11 |
high concern | 11 |
four non | 11 |
runny nose | 11 |
medical college | 11 |
interaction term | 11 |
symptomatic patients | 11 |
detecting influenza | 11 |
artery disease | 11 |
million deaths | 11 |
among different | 11 |
intervention measures | 11 |
aspartate aminotransferase | 11 |
pandemic season | 11 |
single nucleotide | 11 |
valent pneumococcal | 11 |
pcr detection | 11 |
lower risk | 11 |
dna polymerase | 11 |
community hospital | 11 |
mrsa isolates | 11 |
nvhap incidence | 11 |
across different | 11 |
controlled trials | 11 |
first day | 11 |
significant role | 11 |
data showed | 11 |
ns rdt | 11 |
th month | 11 |
old age | 11 |
first confirmed | 11 |
younger children | 11 |
dromedary camels | 11 |
liver disease | 11 |
protein vaccine | 11 |
control program | 11 |
also observed | 11 |
low level | 11 |
eight patients | 11 |
health system | 11 |
viral diagnosis | 11 |
bivariate analysis | 11 |
input parameters | 11 |
data interpretation | 11 |
china clinical | 11 |
also thank | 11 |
ai outbreaks | 11 |
patient developed | 11 |
age years | 11 |
human subjects | 11 |
safety network | 11 |
measured using | 11 |
clinical microbiology | 11 |
negative perceptions | 11 |
healthcare safety | 11 |
clinical impact | 11 |
mrsa strains | 11 |
poultry farms | 11 |
lyantonde district | 11 |
moraxella nonliquefaciens | 11 |
arv prophylaxis | 11 |
different hospital | 11 |
amplification assay | 11 |
ns ag | 11 |
infection surveillance | 11 |
radiological findings | 11 |
patients underwent | 11 |
also known | 11 |
ferret badgers | 11 |
also included | 11 |
studies conducted | 11 |
hematopoietic stem | 11 |
singapore military | 11 |
significant increase | 11 |
four hpiv | 11 |
paediatric patients | 11 |
cmv reactivation | 11 |
outcome measures | 11 |
four days | 11 |
cycle threshold | 11 |
candida albicans | 11 |
arterial blood | 11 |
viral pathogen | 11 |
attending day | 11 |
temporal analysis | 11 |
fatal case | 11 |
cerebrospinal fluid | 11 |
seasonal variation | 11 |
mycoplasma pneumonia | 11 |
prospective observational | 11 |
transmission patterns | 11 |
detected virus | 11 |
health status | 11 |
found among | 11 |
patient ratio | 11 |
metagenomic analysis | 11 |
positive correlation | 11 |
confirmed mers | 11 |
perceived effectiveness | 11 |
multiple respiratory | 11 |
china cdc | 11 |
animals inoculated | 11 |
parameter estimates | 11 |
evaluated using | 11 |
clinical evidence | 11 |
recovery rate | 11 |
final concentration | 11 |
viridans streptococcal | 11 |
reverse primer | 11 |
rhino entero | 11 |
mers coronavirus | 11 |
raw data | 11 |
factor associated | 11 |
secondary cluster | 11 |
orf ab | 11 |
viruses associated | 11 |
multiple regression | 11 |
multivariate analyses | 11 |
future research | 11 |
household member | 11 |
available data | 11 |
also performed | 11 |
human transmission | 11 |
spatial scan | 11 |
infected people | 11 |
implementation strategy | 11 |
overall hiv | 11 |
seasonal distribution | 11 |
treatment initiation | 11 |
qualitative data | 11 |
training base | 11 |
school children | 11 |
younger age | 11 |
medical workers | 11 |
relatively low | 11 |
respiratory system | 11 |
platelet count | 11 |
rates among | 11 |
associated picu | 11 |
national healthcare | 11 |
health departments | 11 |
chronic diseases | 11 |
public hospitals | 11 |
time interval | 11 |
health measures | 10 |
patients developed | 10 |
acute febrile | 10 |
manuscript writing | 10 |
ward staff | 10 |
significantly less | 10 |
old female | 10 |
one child | 10 |
lower sensitivity | 10 |
acute gastroenteritis | 10 |
total amount | 10 |
children attending | 10 |
including age | 10 |
fluid resuscitation | 10 |
surveyed eds | 10 |
monoclonal antibody | 10 |
genetic factors | 10 |
nucleotide polymorphisms | 10 |
aortic valve | 10 |
disease outcome | 10 |
case study | 10 |
higher sensitivity | 10 |
experimentally mapped | 10 |
lung infiltrates | 10 |
series analysis | 10 |
protein expression | 10 |
cell lines | 10 |
study periods | 10 |
sputum culture | 10 |
different groups | 10 |
influenza disease | 10 |
major cause | 10 |
acute care | 10 |
xenon ultraviolet | 10 |
active screening | 10 |
penton genes | 10 |
forward primer | 10 |
sequence analysis | 10 |
transmission characteristics | 10 |
national university | 10 |
pulmonary embolism | 10 |
daily cumulative | 10 |
acute viral | 10 |
seasonal decomposition | 10 |
low birth | 10 |
global spread | 10 |
cfu per | 10 |
epidemic situation | 10 |
false positives | 10 |
routine surveillance | 10 |
nucleotide identity | 10 |
three weeks | 10 |
individual assays | 10 |
hand disinfection | 10 |
potential confounders | 10 |
two days | 10 |
rsv assay | 10 |
malaria hotspots | 10 |
details key | 10 |
practice guidelines | 10 |
among pediatric | 10 |
cell quantification | 10 |
two independent | 10 |
virus isolation | 10 |
human disease | 10 |
outcome data | 10 |
demographic factors | 10 |
outcomes among | 10 |
poc test | 10 |
drug resistant | 10 |
household ili | 10 |
well established | 10 |
adenovirus serotype | 10 |
incubation periods | 10 |
sequence alignment | 10 |
mechanically ventilated | 10 |
viral culture | 10 |
next day | 10 |
tb cases | 10 |
interferon beta | 10 |
resistant enterococcus | 10 |
primer set | 10 |
short time | 10 |
poultry markets | 10 |
acid detection | 10 |
lactate dehydrogenase | 10 |
also play | 10 |
ag elisa | 10 |
ethics review | 10 |
maternal near | 10 |
among others | 10 |
detection fraction | 10 |
community residents | 10 |
cases occurred | 10 |
feeding options | 10 |
frequent detection | 10 |
first cases | 10 |
analysis using | 10 |
southeast asia | 10 |
negative controls | 10 |
congenital heart | 10 |
unknown etiology | 10 |
serotype distribution | 10 |
south wales | 10 |
study provides | 10 |
ms ms | 10 |
bundle elements | 10 |
complement factor | 10 |
using data | 10 |
major public | 10 |
microbiology laboratory | 10 |
respiratory organisms | 10 |
transcription pcr | 10 |
every day | 10 |
neonatal outcomes | 10 |
bacterial coinfections | 10 |
risk perceptions | 10 |
blood urea | 10 |
aspergillus spp | 10 |
schistosoma mansoni | 10 |
adult population | 10 |
new influenza | 10 |
detected among | 10 |
based studies | 10 |
forming units | 10 |
statistically significantly | 10 |
mrsa rates | 10 |
patients included | 10 |
high detection | 10 |
sectional survey | 10 |
appropriate treatment | 10 |
gastrointestinal tract | 10 |
klebsiella pneumoniae | 10 |
google flu | 10 |
comparative study | 10 |
deaths worldwide | 10 |
diagnostic tools | 10 |
ultraviolet light | 10 |
positive control | 10 |
correlation analysis | 10 |
among cases | 10 |
ns elisa | 10 |
children presenting | 10 |
hospitalized adults | 10 |
main study | 10 |
overall mortality | 10 |
implementation outcomes | 10 |
low incidence | 10 |
average temperature | 10 |
patient samples | 10 |
bacterial community | 10 |
important intellectual | 10 |
manual cleaning | 10 |
randomised trial | 10 |
chest pain | 10 |
toxascaris infection | 10 |
accompanying images | 10 |
human skin | 10 |
medical mask | 10 |
medical condition | 10 |
paediatric intensive | 10 |
pdm pandemic | 10 |
tertiary peritonitis | 10 |
cases within | 10 |
passenger lists | 10 |
case definitions | 10 |
care settings | 10 |
person transmission | 10 |
respiratory medicine | 10 |
structured questionnaire | 10 |
virus strains | 10 |
flight arrival | 10 |
dengue haemorrhagic | 10 |
control policies | 10 |
least three | 10 |
serological tests | 10 |
ethics committees | 10 |
respiratory secretions | 10 |
thank dr | 10 |
pcr positive | 10 |
pediatric intensive | 10 |
colombian patients | 10 |
replacement therapy | 10 |
toxocara cati | 10 |
risk communication | 10 |
published article | 10 |
preterm labor | 10 |
ct imaging | 10 |
real data | 10 |
multiplex rt | 10 |
epitope prediction | 10 |
poisson model | 10 |
previously identified | 10 |
old man | 10 |
pneumonia clinical | 10 |
withdrawal group | 10 |
viral genome | 10 |
igg rdt | 10 |
lyantonde hospital | 10 |
infections associated | 10 |
onset date | 10 |
maripa virus | 10 |
reaction assay | 10 |
bloodstream infection | 10 |
low bacterial | 10 |
results show | 10 |
military environment | 10 |
renal replacement | 10 |
secondary infections | 10 |
bird market | 10 |
lavage fluid | 10 |
interferon alpha | 10 |
northern hemisphere | 10 |
legionella pneumophila | 10 |
genbank accession | 10 |
weather conditions | 10 |
national institute | 10 |
hbov positive | 10 |
days post | 10 |
data reported | 10 |
samples obtained | 10 |
requiring invasive | 10 |
nontuberculous mycobacterial | 10 |
higher prevalence | 10 |
coronavirus rna | 10 |
also identified | 10 |
mass spectrometry | 10 |
systematic literature | 10 |
coxsackie echovirus | 10 |
per patient | 10 |
igg antibody | 10 |
rh proteins | 10 |
information needs | 10 |
temporal cluster | 10 |
antiviral drug | 10 |
published data | 10 |
hpiv infection | 10 |
low positive | 10 |
received antiviral | 10 |
health protective | 10 |
pneumonia induced | 10 |
left ventricular | 10 |
new south | 10 |
following symptoms | 10 |
several factors | 10 |
western region | 10 |
identified using | 10 |
aspiration risk | 10 |
two hospitals | 10 |
specimens using | 10 |
primary health | 10 |
search term | 10 |
using multiplex | 10 |
statistical package | 10 |
borne diseases | 10 |
viral targets | 10 |
dna extraction | 10 |
people living | 9 |
analysis based | 9 |
care home | 9 |
converting enzyme | 9 |
cellular immune | 9 |
atypical bacteria | 9 |
medical visit | 9 |
outcome measure | 9 |
clinical evaluation | 9 |
nvhap prevention | 9 |
binary logistic | 9 |
control procedures | 9 |
immune systems | 9 |
limited number | 9 |
ferret badger | 9 |
relatively small | 9 |
direct sequencing | 9 |
significantly differ | 9 |
first medical | 9 |
highest incidence | 9 |
human populations | 9 |
virus panel | 9 |
epidemic years | 9 |
resistant acinetobacter | 9 |
clinical improvement | 9 |
gas analysis | 9 |
broad range | 9 |
temporal changes | 9 |
secondary data | 9 |
health service | 9 |
samples containing | 9 |
medical resources | 9 |
prevalence rate | 9 |
patients whose | 9 |
fold higher | 9 |
cape town | 9 |
implementation period | 9 |
community nurses | 9 |
contributed equally | 9 |
suspected covid | 9 |
negative binomial | 9 |
initial phase | 9 |
common viruses | 9 |
rpa assay | 9 |
spanish influenza | 9 |
clinical condition | 9 |
specific pathogens | 9 |
renal disease | 9 |
young adult | 9 |
anterior nasal | 9 |
initial symptoms | 9 |
unit admission | 9 |
suspected measles | 9 |
human toxocara | 9 |
virus surveillance | 9 |
national level | 9 |
chronic medical | 9 |
mild symptoms | 9 |
studies comparing | 9 |
specimens collected | 9 |
circulating anodic | 9 |
new human | 9 |
influenza risk | 9 |
intermittent infusion | 9 |
research institute | 9 |
also collected | 9 |
causative pathogens | 9 |
sectional surveys | 9 |
clinical severity | 9 |
egg microscopy | 9 |
resistant enterococci | 9 |
birth weight | 9 |
index tests | 9 |
without severe | 9 |
frequently reported | 9 |
rabies virus | 9 |
required admission | 9 |
samples using | 9 |
relative susceptibility | 9 |
washing hands | 9 |
normal population | 9 |
positive mothers | 9 |
health behaviours | 9 |
limited data | 9 |
two parameters | 9 |
small proportion | 9 |
public venues | 9 |
novel avian | 9 |
surveillance officers | 9 |
transport media | 9 |
retrospective studies | 9 |
infection due | 9 |
reported previously | 9 |
respiratory infectious | 9 |
epidemic length | 9 |
two waves | 9 |
time course | 9 |
chronic pulmonary | 9 |
population size | 9 |
disease confirmation | 9 |
multiple comparisons | 9 |
national immunization | 9 |
health evaluation | 9 |
relevant journal | 9 |
low concentrations | 9 |
coxiella burnetii | 9 |
sinus tachycardia | 9 |
type ii | 9 |
pregnant patients | 9 |
supportive care | 9 |
modified protocol | 9 |
epidemiological investigation | 9 |
extraction method | 9 |
visible mould | 9 |
wilcoxon rank | 9 |
robert koch | 9 |
female patients | 9 |
significant effect | 9 |
nursing home | 9 |
quantitative variables | 9 |
education level | 9 |
sd patients | 9 |
emergency room | 9 |
strains isolated | 9 |
experimental data | 9 |
flow cytometry | 9 |
based assays | 9 |
health concern | 9 |
positively correlated | 9 |
higher frequency | 9 |
within months | 9 |
health information | 9 |
study suggests | 9 |
patient age | 9 |
telephone survey | 9 |
analyzed data | 9 |
older children | 9 |
western blotting | 9 |
viruses among | 9 |
disease associated | 9 |
first report | 9 |
primary endpoint | 9 |
viral testing | 9 |
medical sciences | 9 |
recruit camp | 9 |
haemophagocytic syndrome | 9 |
china national | 9 |
molecular analysis | 9 |
av treatment | 9 |
plasma sample | 9 |
causative pathogen | 9 |
hand disinfectant | 9 |
regression analyses | 9 |
environmental samples | 9 |
spatial scanning | 9 |
accept pre | 9 |
first affiliated | 9 |
cardiovascular disease | 9 |
tuberculosis drug | 9 |
population level | 9 |
flu trends | 9 |
accurate diagnosis | 9 |
oral care | 9 |
dry cough | 9 |
ebola virus | 9 |
will need | 9 |
notifiable disease | 9 |
mdrgn transmission | 9 |
temperate climates | 9 |
crowded places | 9 |
acquired respiratory | 9 |
tropical medicine | 9 |
primary cases | 9 |
medical research | 9 |
full implementation | 9 |
million people | 9 |
generation cephalosporin | 9 |
wide variety | 9 |
urine samples | 9 |
culture negative | 9 |
among pregnant | 9 |
pathogens associated | 9 |
healthy subjects | 9 |
white cell | 9 |
immunization program | 9 |
associated mortality | 9 |
monte carlo | 9 |
personal protection | 9 |
severe infections | 9 |
right lower | 9 |
emerging infections | 9 |
cytokine profiles | 9 |
positive ct | 9 |
health research | 9 |
whole blood | 9 |
southern taiwan | 9 |
spatial distribution | 9 |
taken together | 9 |
negatively correlated | 9 |
disseminated adenovirus | 9 |
cases may | 9 |
contact investigations | 9 |
reaction assays | 9 |
western blot | 9 |
fold increase | 9 |
children respiratory | 9 |
study aimed | 9 |
preschool children | 9 |
infectious agent | 9 |
children hospitalised | 9 |
significantly reduced | 9 |
ili events | 9 |
cumulative cases | 9 |
large numbers | 9 |
global spatial | 9 |
community outbreak | 9 |
severity relative | 9 |
even higher | 9 |
quantitative real | 9 |
water deer | 9 |
anodic antigen | 9 |
sinti population | 9 |
work experience | 9 |
pediatric respiratory | 9 |
study subjects | 9 |
two countries | 9 |
leptospirosis patients | 9 |
include fever | 9 |
cluster area | 9 |
demographic variables | 9 |
simulation engine | 9 |
clinical spectrum | 9 |
pandemic preparedness | 9 |
analysis will | 9 |
sas institute | 9 |
well known | 9 |
international spread | 9 |
new diagnostic | 9 |
possible explanation | 9 |
mortality among | 9 |
routine diagnostic | 9 |
fever positive | 9 |
prevalence rates | 9 |
point estimates | 9 |
trial registration | 9 |
acute lymphoblastic | 9 |
change coefficient | 9 |
perceived severity | 9 |
three viruses | 9 |
rna copies | 9 |
hygiene practices | 9 |
pulmonary syndrome | 9 |
tertiary referral | 9 |
completion group | 9 |
primary vitro | 9 |
spectrum beta | 9 |
chronic health | 9 |
syndrome caused | 9 |
false negatives | 9 |
chest computed | 9 |
side effects | 9 |
improved detection | 9 |
samples positive | 9 |
fatal outcome | 9 |
fast assay | 9 |
measles elimination | 9 |
decomposition analysis | 9 |
less severe | 9 |
causative agents | 9 |
patients also | 9 |
recombinant baculoviruses | 9 |
maximum likelihood | 9 |
virologically suppressed | 9 |
acid kit | 9 |
novel human | 9 |
amino acids | 9 |
transmission processes | 9 |
agglutination test | 9 |
grant number | 9 |
complications attributable | 9 |
infection associated | 9 |
untreated patients | 9 |
immune cells | 9 |
acute infections | 9 |
observational cohort | 9 |
outbreak investigation | 9 |
total igg | 9 |
disease incidence | 9 |
positive case | 9 |
also considered | 9 |
patients treated | 9 |
multicenter study | 9 |
arterial pressure | 9 |
will use | 9 |
mass vaccination | 9 |
recently published | 9 |
long term | 9 |
communicable diseases | 9 |
potential confounding | 9 |
molecular biology | 9 |
seven patients | 9 |
febrile passengers | 9 |
potential role | 9 |
within co | 9 |
indirect immunofluorescence | 9 |
positive detection | 9 |
normally distributed | 9 |
viral loads | 9 |
global epidemic | 9 |
inactivated sars | 9 |
new zealand | 9 |
clinical isolates | 9 |
behavioral associations | 9 |
schistosoma haematobium | 9 |
collect data | 9 |
positive rt | 9 |
initial pathogen | 9 |
skin rash | 9 |
two consecutive | 9 |
food production | 9 |
hbov prevalence | 9 |
ethical committee | 9 |
severe outcomes | 9 |
identify potential | 9 |
therapy completion | 9 |
vast majority | 9 |
reference number | 9 |
salt lake | 9 |
report date | 9 |
children may | 9 |
inos activity | 9 |
provide care | 9 |
extraction kit | 9 |
picu admission | 9 |
spa typing | 9 |